MSLN and neoplasm: However, Katz et al. recently confirmed the correlation of SMRP and fibulin-3 with initial tumor volume, but recent studies have failed to demonstrate the clinical utility of the biomarkers in terms of assessing the tumor response in patients receiving immunotherapy [81].